Developer docs
API playgroundTry for free, no card

Search company profiles

Poly Medicure

Full company profile

uuid000226s

Namestring
Poly Medicure
Legal namestring
Poly Medicure Limited
Company typeenum
Public
Founded yearint
1995
Descriptiontext

Poly Medicure Limited is an Indian medical device manufacturer founded in 1995 and publicly listed on the BSE and NSE under the POLYMED ticker. The company designs and manufactures a portfolio of interventional medical devices spanning cardiovascular and renal care product lines. Core products include coronary stents (with cumulative deployments exceeding 11,000 units), drug-eluting balloons (commercially launched in FY26), dialysis machines (with an installed base of approximately 1,000 units), prefilled syringes, and vascular access catheters. Manufacturing operations include facilities in Faridabad, with a registered office in New Delhi, and a workforce of 1,001-5,000 employees.

The business model is direct enterprise hardware sales to healthcare providers — hospitals, dialysis centers, and medical facilities — across both domestic and international markets. Exports account for 65%+ of revenue, with the United States, Europe, and other international markets as key destinations. Government policy support, including India's Production Linked Incentive (PLI) scheme and the National Medical Devices Policy, combined with US tariff reductions (from 50% to 18%), creates a structural cost advantage versus Chinese manufacturers facing 30-34% tariffs. FY26 revenue reached Rs 1,875.26 crore (12.3% year-over-year growth), with management guiding FY27 revenue to Rs 2,300-2,400 crore on 20% domestic and 15% international growth targets.

Poly Medicure combines organic expansion with M&A and capital markets activity. The company acquired Pendracare in September 2025 and raised Rs 1,000 crore through a Qualified Institutional Placement in August 2024, with participation from Lighthouse India Fund IV AIF and other institutional funds. Managing Director Himanshu Baid was appointed Senior Vice President of NATHEALTH (Healthcare Federation of India) for FY 2026-27, positioning the company within industry advocacy. Recent performance shows revenue acceleration but compressed profitability — EBITDA margin contracted to 20.6-21% in FY26 from 27.1% the prior year, and net profit declined 4.85% to Rs 322.14 crore — reflecting rising input costs and operating expense investment to support growth.

Short descriptiontext

Poly Medicure is an Indian medical device manufacturer producing coronary stents, drug-eluting balloons, dialysis machines, and prefilled syringes. It serves hospitals and healthcare providers domestically and across 65%+ export markets, with FY26 revenue of Rs 1,875 crore.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersNew Delhi, India
HQ citystring
New Delhi
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical device manufacturing, cardiac intervention devices, dialysis equipment, vascular access devices, prefilled syringes
Industry2 codes
1Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)
CodeHLAHANAGPrimaryYes
2Medical Supplies & Consumables Wholesale (Non-Device)
CodeCRAOAHAEPrimaryNo
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Manufacturing and Sales
TypeHardware Sales
Description

Poly Medicure generates revenue through the manufacture and sale of medical devices including stents, prefilled syringes, vascular catheters, dialysis equipment, and related consumables. Revenue grew 12.30% year-over-year to Rs 1,875.26 crore in FY26, with Q4 FY26 revenue at Rs 534.51 crore representing 21.25% growth.

business-standard.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Poly Medicure manufactures and sells a diversified portfolio of medical devices for hospitals, dialysis centers, and international healthcare buyers. Core products include coronary stents, drug-eluting balloons, dialysis machines and consumables, prefilled syringes, and vascular access devices and catheters. The company reports FY26 revenue of Rs 1,875.26 crore with 65%+ derived from international export markets and 35% from the domestic Indian healthcare sector.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Revenue growth of 12.3% to ₹1,875 crore in FY26
+2 more records
Product overview1 text field

Poly Medicure is a medical device manufacturer offering a portfolio of interventional cardiac and renal care products. The core offerings include coronary stents (with over 11,000 cumulative deployments), drug-eluting balloons (newly launched in FY26), and dialysis machines for end-stage renal disease treatment. The company operates primarily in the healthcare/medical technology sector, serving domestic and international markets with medical devices that address cardiovascular and renal care needs.

Product and service5 records
1Coronary Stents
CategoryInterventional Cardiology
Description

Coronary stents used in cardiac interventions by hospitals and interventional cardiology departments, forming part of Poly Medicure's established interventional cardiology portfolio.

2Drug-Eluting Balloons
CategoryInterventional Cardiology
Description

Drug-eluting balloons used in cardiac and vascular interventions for hospitals and interventional cardiology specialists, representing a new product line in Poly Medicure's vascular intervention portfolio.

3Dialysis Machines
CategoryRenal Care
Description

Dialysis machines for renal care sold to hospitals and dialysis centers for end-stage renal disease treatment, forming part of Poly Medicure's renal therapy portfolio.

4Prefilled Syringes
CategoryMedical Consumables
Description

Prefilled syringes sold to hospitals and healthcare providers for general medical procedures, included in Poly Medicure's diversified medical device portfolio.

5Vascular Access Devices and Catheters
CategoryVascular Access
Description

Vascular access devices and catheters for vascular interventions and general medical procedures, sold to hospitals and healthcare providers.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Poly Medicure's Managing Director Himanshu Baid serves as Senior Vice President of NATHEALTH for FY 2026-27, actively participating in healthcare policy advocacy and industry leadership alongside Dr. Sangita Reddy (President) and Varun Khanna (Vice President).

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Hindustan Syringes & Medical Devices
TypeDirect peer
Description

India-based manufacturer of disposable syringes, needles, and medical devices with overlapping product lines and similar hospital customer base. HMD is a direct competitor in prefilled syringes and disposable medical devices, with comparable export-driven business model.

TypeDirect peer
Description

Japanese global medical device manufacturer with strong franchises in prefilled syringes, drug-eluting stents, and cardiovascular intervention products. Directly comparable product portfolio and similar hospital/cardiologist end-market.

TypeDirect peer
Description

Global leader in prefilled syringes, drug delivery systems, and vascular access devices — directly competing with Poly Medicure's syringe and vascular catheter franchises, with shared hospital customers worldwide.

TypeDirect peer
Description

Japanese medical device manufacturer with strong franchises in dialysis machines and consumables, syringes, and vascular devices. Highly comparable product overlap in renal care and prefilled syringes.

TypeBroad incumbent
Description

German multinational with broad medical device portfolio spanning infusion therapy, syringes, surgical instruments, and dialysis. Overlaps with Poly Medicure across multiple product lines but operates as a much larger incumbent.

TypeBroad incumbent
Description

Global dialysis market leader providing dialysis machines, dialyzers, and renal care services. Directly comparable to Poly Medicure's ~1,000-machine installed base, but operating at vastly larger scale and with vertically integrated services.

TypeBroad incumbent
Description

World's largest medical device company with dominant franchises in coronary stents, drug-eluting stents, and cardiac intervention. Directly comparable to Poly Medicure's stent portfolio but vastly larger scale and global reach.

TypeBroad incumbent
Description

Global medical device leader with major franchises in vascular intervention, drug-eluting stents, and cardiac devices. Comparable product overlap in coronary stents and vascular access, operating at multinational scale.

TypeEmerging player
Description

India-based medical device company developing and manufacturing cardiovascular devices including stents and heart valves. Direct domestic peer competing in similar Indian hospital channels with comparable product focus.

TypeEmerging player
Description

India-based medical devices company focused on surgical consumables, wound closure, and orthopedics. Comparable India-based manufacturing model targeting similar hospital procurement channels, with adjacent rather than directly overlapping product lines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Poly Medicure

Medical Devicespolymedicure.com

Poly Medicure is an Indian medical device manufacturer producing coronary stents, drug-eluting balloons, dialysis machines, and prefilled syringes. It serves hospitals and healthcare providers domestically and across 65%+ export markets, with FY26 revenue of Rs 1,875 crore.

What Poly Medicure does

Poly Medicure Limited is an Indian medical device manufacturer founded in 1995 and publicly listed on the BSE and NSE under the POLYMED ticker. The company designs and manufactures a portfolio of interventional medical devices spanning cardiovascular and renal care product lines. Core products include coronary stents (with cumulative deployments exceeding 11,000 units), drug-eluting balloons (commercially launched in FY26), dialysis machines (with an installed base of approximately 1,000 units), prefilled syringes, and vascular access catheters. Manufacturing operations include facilities in Faridabad, with a registered office in New Delhi, and a workforce of 1,001-5,000 employees.

The business model is direct enterprise hardware sales to healthcare providers — hospitals, dialysis centers, and medical facilities — across both domestic and international markets. Exports account for 65%+ of revenue, with the United States, Europe, and other international markets as key destinations. Government policy support, including India's Production Linked Incentive (PLI) scheme and the National Medical Devices Policy, combined with US tariff reductions (from 50% to 18%), creates a structural cost advantage versus Chinese manufacturers facing 30-34% tariffs. FY26 revenue reached Rs 1,875.26 crore (12.3% year-over-year growth), with management guiding FY27 revenue to Rs 2,300-2,400 crore on 20% domestic and 15% international growth targets.

Poly Medicure combines organic expansion with M&A and capital markets activity. The company acquired Pendracare in September 2025 and raised Rs 1,000 crore through a Qualified Institutional Placement in August 2024, with participation from Lighthouse India Fund IV AIF and other institutional funds. Managing Director Himanshu Baid was appointed Senior Vice President of NATHEALTH (Healthcare Federation of India) for FY 2026-27, positioning the company within industry advocacy. Recent performance shows revenue acceleration but compressed profitability — EBITDA margin contracted to 20.6-21% in FY26 from 27.1% the prior year, and net profit declined 4.85% to Rs 322.14 crore — reflecting rising input costs and operating expense investment to support growth.

Poly Medicure firmographics

Firmographics
Name
Poly Medicure
Legal name
Poly Medicure Limited
Website
https://polymedicure.com
Company type
Public
Founded year
1995
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Poly Medicure is an Indian medical device manufacturer producing coronary stents, drug-eluting balloons, dialysis machines, and prefilled syringes. It serves hospitals and healthcare providers domestically and across 65%+ export markets, with FY26 revenue of Rs 1,875 crore.
Ownership category
akta.pro rank

Poly Medicure industry classification

Industry
Product category
Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro primary industry
Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG)
akta.pro secondary industry
Medical Supplies & Consumables Wholesale (Non-Device) (CRAOAHAE)

Keywords

  • Medical device manufacturing
  • Cardiac intervention devices
  • Dialysis equipment
  • Vascular access devices
  • Prefilled syringes

Where Poly Medicure is headquartered

Location

Headquarters

HQ city
New Delhi
HQ country
India
HQ region
Asia

Offices2 records

Markets served

Poly Medicure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Manufacturing and Sales: Poly Medicure generates revenue through the manufacture and sale of medical devices including stents, prefilled syringes, vascular catheters, dialysis equipment, and related consumables. Revenue grew 12.30% year-over-year to Rs 1,875.26 crore in FY26, with Q4 FY26 revenue at Rs 534.51 crore representing 21.25% growth.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Poly Medicure product offering

Product offering

Core offering

Poly Medicure manufactures and sells a diversified portfolio of medical devices for hospitals, dialysis centers, and international healthcare buyers. Core products include coronary stents, drug-eluting balloons, dialysis machines and consumables, prefilled syringes, and vascular access devices and catheters. The company reports FY26 revenue of Rs 1,875.26 crore with 65%+ derived from international export markets and 35% from the domestic Indian healthcare sector.

Product overview

Poly Medicure is a medical device manufacturer offering a portfolio of interventional cardiac and renal care products. The core offerings include coronary stents (with over 11,000 cumulative deployments), drug-eluting balloons (newly launched in FY26), and dialysis machines for end-stage renal disease treatment. The company operates primarily in the healthcare/medical technology sector, serving domestic and international markets with medical devices that address cardiovascular and renal care needs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Coronary Stents Coronary stents used in cardiac interventions by hospitals and interventional cardiology departments, forming part of Poly Medicure's established interventional cardiology portfolio.
  • Drug-Eluting Balloons Drug-eluting balloons used in cardiac and vascular interventions for hospitals and interventional cardiology specialists, representing a new product line in Poly Medicure's vascular intervention portfolio.
  • Dialysis Machines Dialysis machines for renal care sold to hospitals and dialysis centers for end-stage renal disease treatment, forming part of Poly Medicure's renal therapy portfolio.
  • Prefilled Syringes Prefilled syringes sold to hospitals and healthcare providers for general medical procedures, included in Poly Medicure's diversified medical device portfolio.
  • Vascular Access Devices and Catheters Vascular access devices and catheters for vascular interventions and general medical procedures, sold to hospitals and healthcare providers.

Quantifiable outcome

  • Revenue growth of 12.3% to ₹1,875 crore in FY26
  • +2 more outcomes

Companies that use Poly Medicure

Customer profile

Segments2 records

Ideal customer profiles1 record

Poly Medicure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Poly Medicure partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NATHEALTH (Healthcare Federation of India)coreStrategic or Co-development PartnerPoly Medicure's Managing Director Himanshu Baid serves as Senior Vice President of NATHEALTH for FY 2026-27, actively participating in healthcare policy advocacy and industry leadership alongside Dr. Sangita Reddy (President) and Varun Khanna (Vice President).

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Poly Medicure competitors and assessment

Company assessment

Direct peers

  • Hindustan Syringes & Medical Devices: India-based manufacturer of disposable syringes, needles, and medical devices with overlapping product lines and similar hospital customer base. HMD is a direct competitor in prefilled syringes and disposable medical devices, with comparable export-driven business model.
  • Terumo Corporation: Japanese global medical device manufacturer with strong franchises in prefilled syringes, drug-eluting stents, and cardiovascular intervention products. Directly comparable product portfolio and similar hospital/cardiologist end-market.
  • Becton Dickinson (BD): Global leader in prefilled syringes, drug delivery systems, and vascular access devices — directly competing with Poly Medicure's syringe and vascular catheter franchises, with shared hospital customers worldwide.
  • Nipro Corporation: Japanese medical device manufacturer with strong franchises in dialysis machines and consumables, syringes, and vascular devices. Highly comparable product overlap in renal care and prefilled syringes.

Broad incumbents

  • B. Braun Melsungen: German multinational with broad medical device portfolio spanning infusion therapy, syringes, surgical instruments, and dialysis. Overlaps with Poly Medicure across multiple product lines but operates as a much larger incumbent.
  • Fresenius Medical Care: Global dialysis market leader providing dialysis machines, dialyzers, and renal care services. Directly comparable to Poly Medicure's ~1,000-machine installed base, but operating at vastly larger scale and with vertically integrated services.
  • Medtronic: World's largest medical device company with dominant franchises in coronary stents, drug-eluting stents, and cardiac intervention. Directly comparable to Poly Medicure's stent portfolio but vastly larger scale and global reach.
  • Abbott Laboratories: Global medical device leader with major franchises in vascular intervention, drug-eluting stents, and cardiac devices. Comparable product overlap in coronary stents and vascular access, operating at multinational scale.

Emerging players

  • Meril Life Sciences: India-based medical device company developing and manufacturing cardiovascular devices including stents and heart valves. Direct domestic peer competing in similar Indian hospital channels with comparable product focus.
  • Healthium Medtech: India-based medical devices company focused on surgical consumables, wound closure, and orthopedics. Comparable India-based manufacturing model targeting similar hospital procurement channels, with adjacent rather than directly overlapping product lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Poly Medicure social profiles

Digital presence

Poly Medicure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Poly Medicure leadership team

Management profile

Number of profiles

Profiles1 record

Poly Medicure funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Poly Medicure M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Poly Medicure

What does Poly Medicure do?

Poly Medicure manufactures and sells a diversified portfolio of medical devices for hospitals, dialysis centers, and international healthcare buyers. Core products include coronary stents, drug-eluting balloons, dialysis machines and consumables, prefilled syringes, and vascular access devices and catheters. The company reports FY26 revenue of Rs 1,875.26 crore with 65%+ derived from international export markets and 35% from the domestic Indian healthcare sector.

Is Poly Medicure a public or private company?

Poly Medicure is a public company. It is classified as public and is currently operating.

When was Poly Medicure founded?

Poly Medicure was founded in 1995. It employs 1,001 to 5,000 people.

Where is Poly Medicure based?

Poly Medicure is headquartered in New Delhi, India, in the Asia region.

How does Poly Medicure make money?

One revenue line is on record: medical Device Manufacturing and Sales.

Who are Poly Medicure's main competitors?

Direct peers on record are Hindustan Syringes & Medical Devices, Terumo Corporation, Becton Dickinson (BD) and Nipro Corporation. Broad incumbents are B. Braun Melsungen, Fresenius Medical Care, Medtronic and Abbott Laboratories. Emerging players are Meril Life Sciences and Healthium Medtech.

Does Poly Medicure have an API?

No public API is recorded for Poly Medicure.

What industry is Poly Medicure in?

Poly Medicure's product category is Medical Devices. Its primary akta.pro industry code is HLAHANAG, Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs), with a secondary code of CRAOAHAE, Medical Supplies & Consumables Wholesale (Non-Device). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessLineAfter two overseas buys, Poly Medicure doubles down on domestic manufacturingPoly Medicure is shifting focus to domestic manufacturing after two overseas acquisitions, planning to launch 25-30 new products annually by FY30. The company expects FY26 turnover of about ₹2,300 crore, with 70% of revenue from exports. New facilities in Haryana and Uttar Pradesh will support cost reduction.ScanXPoly Medicure schedules investor meet with Avendus Spark on Sept 30Poly Medicure Limited will host a one-on-one meeting with Avendus Spark on September 30, 2026, at 10:00 am at its Ballabgarh plant in Haryana. The session includes a plant visit, and no unpublished price-sensitive information will be disclosed. The schedule is subject to change due to exigencies.ScanXPoly Medicure schedules analyst meet with ICICI Securities on Sep 24Poly Medicure scheduled a one-on-one analyst meeting with ICICI Securities PMS for September 24, 2026, at its New Delhi office. The disclosure, made under SEBI LODR Regulation 30, stated no unpublished price-sensitive information would be shared. The schedule remains subject to change.ScanXPoly Medicure to hold investor meets on Aug 27, 31Poly Medicure Limited has scheduled one-on-one investor and analyst meetings for August 27 and August 31, 2026, to provide business updates in compliance with SEBI listing regulations. The sessions will involve Bandhan AMC and Sparx Capital, with the company confirming that no unpublished price-sensitive information will be disclosed during these interactions.ScanXPoly Medicure schedules investor meet with Wasatch, Bajaj on Aug 20Poly Medicure Limited has scheduled virtual one-on-one investor meetings with Wasatch Global and Bajaj Alternative Investment Ltd on August 20, 2026. The company disclosed this schedule via a filing to the BSE and NSE, confirming that no unpublished price-sensitive information will be shared during these interactions.ScanXPoly Medicure schedules 31st AGM for September 5, 2026Poly Medicure Ltd has scheduled its 31st Annual General Meeting (AGM) for September 5, 2026, with a formal notice published on August 15, 2026. The AGM will address standard procedural items such as the adoption of financial statements and appointment of auditors. This announcement serves as a routine corporate governance disclosure without introducing new operational or financial developments.News9liveThree shares for up to 10% gains: Picked by brokerage; check target price, stop lossChoice Equity Broking recommended buying shares of Poly Medicure, Ather Energy, and Cohance Lifesciences for potential gains of up to 10% amid recent market volatility. The brokerage cited strong technical signals and bullish trends for these stocks, providing specific target prices and stop-loss levels for investors.YahooPoly Medicure Ltd (BOM:531768) (Q1 2027) Earnings Call Highlights: Strong EBITDA Beat and ...Poly Medicure Ltd reported strong financial results for Q1 2027, with standalone revenue reaching INR431 crores, a 12.3% increase year-on-year, and consolidated revenue of INR525 crores, up 30.3%. The company also exceeded its guidance for standalone EBITDA margin, achieving 28%, and highlighted growth in its cardiology segment, attributed to recent acquisitions. Looking ahead, Poly Medicure maintains optimistic FY27 guidance with a strong pipeline of new product launches.Investing.comEarnings call transcript: Poly Medicure beats Q1 2026 estimates, shares rise 4.6% By Investing.comPoly Medicure Limited reported Q1 FY2027 earnings that beat Wall Street estimates, with EPS of 7.00 versus forecast of 6.78 and revenue of 5.35 billion versus forecast of 5.21 billion. The stock rose 4.61% to $1,771.9 as standalone EBITDA margin came in at 28%, above the guided 25-27% range. The company reiterated its full-year guidance and unveiled PolyMed 3.0, targeting to double revenue by FY2030, with 80% expected from organic growth and 20% from acquisitions.Business StandardVolumes spurt at EID Parry (India) Ltd counterEID Parry (India) Ltd experienced a significant increase in trading volume, with 4.08 lakh shares traded, a 13.63-fold rise over its two-week average. Several other Indian stocks, including Poly Medicure Ltd, Hitachi Energy India Ltd, BEML Ltd, and Grasim Industries Ltd, also saw volume surges and stock price increases on 10 August 2026.